Physician profile
Renetta E Brewer
NPI 1750733408
$5,413.07
in general payments reported to CMS, 2019-2025
21 companies · $1,763 in 2025
The $1,763 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.29 · 2022: $681 · 2023: $1,336 · 2024: $1,622 · 2025: $1,763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,661 · Education: $60.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,661.17 |
| Education | $60.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,167.86 | 2021-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $632.07 | 2022-2025 | Terlivaz, Acthar |
| Otsuka America Pharmaceutical, INC. | $565.92 | 2022-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $406.33 | 2022-2025 | |
| Travere Therapeutics, INC. | $398.67 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $355.82 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $331.50 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $291.23 | 2023-2025 | Jardiance |
| Vifor Pharma, INC. | $290.70 | 2022-2025 | Veltassa, Korsuva |
| Amgen INC. | $190.86 | 2022-2025 | Tavneos |
| Ardelyx, INC. | $171.38 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $170.51 | 2024-2025 | Jardiance |
| Recor Medical INC | $103.56 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Fresenius USA Marketing, INC. | $69.41 | 2022-2025 | Velphoro, Velphoro |
| Glaxosmithkline, LLC. | $68.90 | 2022-2023 | Benlysta |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $55.37 | 2025 | Ultomiris |
| Opko Pharmaceuticals, LLC | $46.44 | 2025 | Rayaldee |
| Aurinia Pharma U.S., INC. | $29.63 | 2025 | Lupkynis |
| Veloxis Pharmaceuticals, INC. | $25.62 | 2024 | Envarsus |
| Apellis Pharmaceuticals, INC. | $22.08 | 2025 | Empaveli |
| Scpharmaceuticals INC. | $19.21 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renetta Brewer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.